纯合M694V基因型家族性地中海热患者的非典型表现:大型患者队列的启示
该研究基于2010至2020年Sheba医疗中心FMF门诊的结构化病历数据,采用自动化算法提取资料,比较纯合M694V基因型患者(517例)与其他基因型患者(3349例)的临床特征。纯合M694V患者需更高秋水仙碱剂量,炎症标志物升高、秋水仙碱治疗失败、白塞病、强直性脊柱炎及慢性肾功能衰竭发生率均更高(均P<0.01),并新发现深静脉血栓(P=0.03)、肝功能障碍(P=0.02)、肝酶异常(P<0.001)及充血性心力衰竭(P=0.01)发生率更高。作者提出全身炎症增强可能解释上述关联,但需进一步探索。
要点
- 纯合M694V患者需更高秋水仙碱剂量,炎症标志物升高及秋水仙碱治疗失败率更高(均P<0.01)。
- 纯合M694V患者白塞病、强直性脊柱炎及慢性肾功能衰竭发生率更高(均P<0.01)。
- 新发现纯合M694V患者深静脉血栓(P=0.03)、肝功能障碍(P=0.02)、肝酶异常(P<0.001)及充血性心力衰竭(P=0.01)发生率更高。
核心结论
- 本研究扩展了纯合M694V相关表型谱,识别出新的非典型特征并在更大规模上强化了既往认识。
- 作者假设全身炎症增强可能解释许多上述关联,但需进一步探索以确定这些新发现是否归因于纯合M694V基因型更强的炎症特性,还是由该FMF亚群中已有的和新的疾病(如白塞病、强直性脊柱炎、充血性心力衰竭、慢性肾功能衰竭及更高秋水仙碱暴露)所介导。
研究设计与样本
- 假设生成性研究,采用自动化算法从Sheba医疗中心FMF门诊2010至2020年随访患者的结构化病历中提取数据。
- 纯合M694V基因型患者(研究组)与其他基因型患者(对照组)进行比较。
主要发现
- 共纳入3866例患者,其中517例(13.4%)为纯合M694V突变,3349例(86.6%)为其他基因型。
- 纯合M694V患者需要更高秋水仙碱剂量,炎症标志物升高率、秋水仙碱治疗失败率、白塞病、强直性脊柱炎及慢性肾功能衰竭发生率均更高(均P<0.01)。
- 新发现包括深静脉血栓(P=0.03)、肝功能障碍(P=0.02)、肝酶异常(P<0.001)及充血性心力衰竭(P=0.01)发生率更高。
- 研究组更多患者接受生物制剂治疗,急诊就诊次数更多,住院率更高(两者均P≤0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步探索以确定这些新发现是否归因于纯合M694V基因型更强的炎症特性,还是由该FMF亚群中已有的和新的疾病(如白塞病、强直性脊柱炎、充血性心力衰竭、慢性肾功能衰竭及更高秋水仙碱暴露)所介导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The homozygous M694V genotype is associated with the most severe form of familial Mediterranean fever (FMF). This study aims to explore whether this genotype is linked not only to classical FMF features, but also to additional, non-canonical manifestations. METHODS: A hypothesis-generating study was conducted using an automated algorithm to extract data from structured medical records of patients followed at the FMF clinic of Sheba Medical Center between 2010 and 2020. Patients homozygous for the M694V genotype (study group) were compared with those having other genotypes (control group). RESULTS: Of 3866 patients, 517 (13.4 %) were homozygous for the M694V mutation, while 3349 (86.6 %) had other genotypes. Homozygous M694V patients required higher colchicine doses and exhibited higher rates of inflammatory markers, colchicine treatment failure, Behcet's disease (BD), ankylosing spondylitis (AS), and chronic renal failure (CRF, in all p < 0.01). New findings included higher rates of deep vein thrombosis (p = 0.03), liver dysfunction (p = 0.02), abnormal liver enzymes (p < 0.001), and congestive heart failure (CHF, p = 0.01). Consequently, more patients in the study group received biologic agents and had more emergency department visits and higher hospitalization rates (p ≤ 0.001 in both). CONCLUSIONS: This study expands the scope of the homozygous M694V-associated phenotype by identifying new non-canonical features and reinforcing previous knowledge on a larger scale. We hypothesized that heightened systemic inflammation may underlie many of these associations. However, further exploration is needed to determine whether these novel findings are indeed attributed to the higher inflammatory nature of the M694V homozygous genotype, or is mediated by established and novel conditions prevailing in this subset of FMF, such as BD, AS, CHF, CRF, and higher colchicine exposure.
引用
- Giat E, Livneh A, Lidar M, et al. Non-canonical manifestations of FMF in homozygous M694V MEFV genotype: Insights from a large patient cohort. Semin Arthritis Rheum. 2025. PMID: 40902213. doi:10.1016/j.semarthrit.2025.152821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。